Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Front Immunol. 2023 Oct 3;14:1255909. doi: 10.3389/fimmu.2023.1255909. eCollection 2023.
The co-occurrence of psoriasis (PsO) and vitiligo is rare in Asian countries, especially in children. This case report presents the first-ever occurrence of PsO combined with vitiligo in an Asian boy under 6 years of age, in whom symptom improvement was observed after the use of methotrexate (MTX) as the sole treatment. Although previous studies have indicated that there is a close correlation between the two diseases, methotrexate (MTX), which is a commonly used treatment for PsO, is not a standard treatment for vitiligo. Even with advanced progress in biologics and Janus kinase inhibitor (JAKi), the biologics and JAKi used in vitiligo are still inconsistent. In our case report, the successful use of MTX indicated that there are shared immune pathways between PsO and vitiligo. Further exploration is needed to optimize the treatment options for this co-occurrence of PsO and vitiligo.
银屑病（PsO）与白癜风同时发生在亚洲国家较为罕见，尤其是在儿童中。本病例报告首次报道了一例 6 岁以下亚洲男孩同时患有 PsO 和白癜风，他仅使用甲氨蝶呤（MTX）治疗后症状得到改善。尽管之前的研究表明这两种疾病密切相关，但甲氨蝶呤（MTX）虽然是一种常用于治疗 PsO 的药物，但不是治疗白癜风的标准药物。即使生物制剂和 Janus 激酶抑制剂（JAKi）取得了进展，白癜风使用的生物制剂和 JAKi 仍不统一。在我们的病例报告中，MTX 的成功使用表明 PsO 和白癜风之间存在共同的免疫途径。需要进一步探索以优化这种 PsO 和白癜风同时发生的治疗选择。
